NVCR - Independent Monitors Suggest Shorter Timeline for Novocure's Lung Cancer Treatment
After reviewing interim results from 210 patients participating in a phase 3 study, an independent monitoring committee is recommending changes to Novocure 's (NASDAQ: NVCR) non-small cell lung cancer (NSCLC) trial. Specifically, the committee is suggesting that the number of patients enrolled in the study be reduced to 278 patients from 534 patients and the patient follow-up period be shortened to 12 months from 18 months.
The committee said it's "likely unnecessary and possibly unethical for patients randomized to the control arm to continue accrual" to the prior enrollment target and timeline.
IMAGE SOURCE: GETTY IMAGES.
For further details see:
Independent Monitors Suggest Shorter Timeline for Novocure's Lung Cancer Treatment